Clinical Trial Update: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating 18F-DTBZ PET imaging as a biomarker for neurodegeneration in PARK6 and PARK8 Parkinsonism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• 18F-DTBZ (fluorine-18 labeled dihydrotetrabenazine)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED